VLS-01 is designed to induce a short psychedelic experience, allowing for a total in-clinic treatment of 2-hours, consistent with an established commercial paradigm in interventional psychiatry VLS-01 ...

Atai Life Sciences and Beckley Psytech announced positive results from a Phase 2b clinical trial evaluating BPL-003, a treatment for treatment-resistant depression (TRD). The study achieved its ...

n (Participants) = number of study participants with at least one event in the corresponding category n (Events) = number of events in the corresponding category and treatment group N = total number ...

atai Life Sciences (ATAI) reported promising data on Tuesday from the second part of a mid-stage trial of BPL-003, a psychedelic therapy being developed by Beckley Psytech, for treatment-resistant ...

Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. ATAI Life Sciences ( (ATAI)) has issued ...

SASKATOON, Saskatchewan--(BUSINESS WIRE)--ZYUS Life Sciences Corporation ("ZYUS" or the “Company”) (TSX-V: ZYUS), a Canadian-based life sciences company leading scientific research and global ...

The stock of small-cap biotech Wave Life Sciences Inc. soared 51% Tuesday after the company reported positive interim data from a mid-stage trial of a treatment for the rare muscle disorder Duchenne ...

Wave Life Sciences shares jumped in premarket trading Monday after it said it received encouraging preliminary trial data for its investigational weight loss drug WVE-007. Shares advanced nearly 78% ...

Study met its primary and all key secondary endpoints, and BPL-003 demonstrated rapid, robust and durable antidepressant effects with a single dose Safety and efficacy results from this study support ...

Stock is on track for its second-biggest one-day gain The stock of small-cap biotech Wave Life Sciences Inc. soared 51% Tuesday after the company reported positive interim data from a mid-stage trial ...